FDA approves Iovance ’s Amtagvi as first T-cell therapy for a solid tumor

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics. Called Amtagvi, or lifileucel, the drug is the first…#fda #pd1 #braf #iovance #frederickvogt #phd #vogt #jimziegler #amtagviwithmerckcos #mariafardis
Source: Reuters: Health - Category: Consumer Health News Source Type: news